<DOC>
	<DOC>NCT00690430</DOC>
	<brief_summary>The purpose of this randomized, multicenter, Phase III study was to compare the efficacy of paseriotide LAR and octreotide LAR in patients whose disease-related symptoms are inadequately controlled by currently available somatostatin analogues.</brief_summary>
	<brief_title>Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease</brief_title>
	<detailed_description />
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Inclusion criteria: Male or female patients aged 18 or greater Patients with carcinoid tumors and symptoms (diarrhea and flushing) that are not adequately controlled by somatostatin analogues. Female patients of child bearing potential must have a negative pregnancy test at baseline. Patients for whom written informed consent to participate in the study has been obtained. Exclusion criteria: Patients receiving radiolabeled somatostatin analogue therapy within the 3 months or any cytotoxic chemotherapy or interferon therapy within the 4 weeks prior to randomization Diabetic patients on antidiabetic medications whose fasting blood glucose is poorly controlled as indicated by HBA1C &gt; 8% Patients with symptomatic cholelithiasis Patient with malabsorption syndrome, short bowel or cholegenic diarrhea not controlled by specific therapeutic means. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Carcinoid</keyword>
	<keyword>neuroendocrine</keyword>
	<keyword>gastroenteropancreatic</keyword>
	<keyword>somatostatin analogue</keyword>
	<keyword>Symptomatic Refractory Resistant Carcinoid Disease</keyword>
</DOC>